PATENT CLAIM ANALYSIS

Application Number: 15884974
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "150000"]

Abstract:
The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 2 ′, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).

Claim (Index 13):
The method of  claim 12 , wherein the cognitive deficit is characterized by impairment of the mental processes of perception, learning, memory, judgment, and/or reasoning.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 86.0
- Lexical Diversity: 1.57627
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15885147', '15502105', '15885258', '14655878', '14898773']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7210350325828763
- 35 USC 102 Novelty (BERT): 0.5412549904525145
- Combined Prediction Score: 0.7030570283698401
- Mean Citation Score: 276.38147999999995
- Max Citation Score: 323.95404
- Similarity Product: 143.0399131772554

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test